small cell lung cancer therapy (Heifei Heyuan Pharmaceutical/NovoTek Therapeutics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namesmall cell lung cancer therapy (Heifei Heyuan Pharmaceutical/NovoTek Therapeutics)
Drug Alias Namehydrochloride shababixing
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHefei Cosource Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesNovotek Pharmaceuticals LtdHefei Cosource Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A